SAN DIEGO--(BUSINESS WIRE)--March 14, 2006--Cytori Therapeutics, Inc. (NASDAQ:CYTX) (Frankfurt:XMPA) announced today that adipose-derived stem cells improved left ventricle wall thickness and capillary density following myocardial infarction in a randomized, placebo-controlled preclinical study. The study, sponsored by Cytori Therapeutics, was presented at the 55th annual meeting of the American College of Cardiology (ACC) (Abstract 829-3).
